CA2890518A1 - Methods for determining if an animal's metabolism is ketogenic - Google Patents
Methods for determining if an animal's metabolism is ketogenic Download PDFInfo
- Publication number
- CA2890518A1 CA2890518A1 CA2890518A CA2890518A CA2890518A1 CA 2890518 A1 CA2890518 A1 CA 2890518A1 CA 2890518 A CA2890518 A CA 2890518A CA 2890518 A CA2890518 A CA 2890518A CA 2890518 A1 CA2890518 A1 CA 2890518A1
- Authority
- CA
- Canada
- Prior art keywords
- animal
- urine sample
- beta
- ketogenic
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 91
- 230000002361 ketogenic effect Effects 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 43
- 230000004060 metabolic process Effects 0.000 title claims abstract description 36
- 210000002700 urine Anatomy 0.000 claims abstract description 81
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims abstract description 46
- 235000005911 diet Nutrition 0.000 claims description 22
- 230000037213 diet Effects 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 4
- 235000020887 ketogenic diet Nutrition 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 208000007976 Ketosis Diseases 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 3
- 230000004140 ketosis Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010023388 Ketonuria Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/20—Oxygen containing
- Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
- Y10T436/201666—Carboxylic acid
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725202P | 2012-11-12 | 2012-11-12 | |
| US61/725,202 | 2012-11-12 | ||
| PCT/US2013/069393 WO2014074972A1 (en) | 2012-11-12 | 2013-11-11 | Methods for determining if an animal's metabolism is ketogenic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2890518A1 true CA2890518A1 (en) | 2014-05-15 |
Family
ID=50682085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2890518A Abandoned CA2890518A1 (en) | 2012-11-12 | 2013-11-11 | Methods for determining if an animal's metabolism is ketogenic |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140134747A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2916655A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016501363A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104768375A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013342056A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015010664A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2890518A1 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2015DN03988A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015005967A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015122704A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014074972A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10668041B2 (en) * | 2014-12-08 | 2020-06-02 | Societe Des Produits Nestle Sa | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4992365A (en) * | 1984-04-23 | 1991-02-12 | Hyman Edward S | Method of detecting bacteria in urine |
| US5510245A (en) * | 1992-09-08 | 1996-04-23 | Bayer Corporation | Composition and method of assaying for ketone bodies |
| US6410063B1 (en) * | 2000-06-13 | 2002-06-25 | Hill's Pet Nutrition, Inc. | Composition and method |
| US20060252775A1 (en) * | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
| CN105640931A (zh) * | 2008-07-03 | 2016-06-08 | 艾克塞拉公司 | 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物 |
| US20110178932A1 (en) * | 2010-01-15 | 2011-07-21 | Anthony Kevin Johnson | Artistic work download transaction (awdt) |
| WO2012113415A1 (en) * | 2011-02-24 | 2012-08-30 | N.V. Nutricia | Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients |
-
2013
- 2013-11-11 WO PCT/US2013/069393 patent/WO2014074972A1/en not_active Ceased
- 2013-11-11 CA CA2890518A patent/CA2890518A1/en not_active Abandoned
- 2013-11-11 AU AU2013342056A patent/AU2013342056A1/en not_active Abandoned
- 2013-11-11 JP JP2015541976A patent/JP2016501363A/ja active Pending
- 2013-11-11 EP EP13852513.4A patent/EP2916655A4/en not_active Withdrawn
- 2013-11-11 CN CN201380058485.3A patent/CN104768375A/zh active Pending
- 2013-11-11 MX MX2015005967A patent/MX2015005967A/es unknown
- 2013-11-11 BR BR112015010664A patent/BR112015010664A2/pt not_active IP Right Cessation
- 2013-11-11 IN IN3988DEN2015 patent/IN2015DN03988A/en unknown
- 2013-11-11 RU RU2015122704A patent/RU2015122704A/ru not_active Application Discontinuation
- 2013-11-11 US US14/076,364 patent/US20140134747A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2916655A1 (en) | 2015-09-16 |
| CN104768375A (zh) | 2015-07-08 |
| MX2015005967A (es) | 2015-09-16 |
| EP2916655A4 (en) | 2015-09-30 |
| RU2015122704A (ru) | 2017-01-10 |
| WO2014074972A1 (en) | 2014-05-15 |
| JP2016501363A (ja) | 2016-01-18 |
| US20140134747A1 (en) | 2014-05-15 |
| AU2013342056A1 (en) | 2015-05-21 |
| IN2015DN03988A (cg-RX-API-DMAC7.html) | 2015-10-02 |
| BR112015010664A2 (pt) | 2017-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Borges et al. | Serum iron and plasma fibrinogen concentrations as indicators of systemic inflammatory diseases in horses | |
| Green et al. | Vitamin B12 deficiency is the dominant nutritional cause of hyperhomocysteinemia in a folic acid-fortified population | |
| Berghoff et al. | Association between serum cobalamin and methylmalonic acid concentrations in dogs | |
| CN103097891B (zh) | 疾病重症度的检查方法 | |
| US10247738B2 (en) | Diagnosing and treating Alzheimers disease | |
| O'Brien et al. | Differential reactivity of cardiac and skeletal muscle from various species in two generations of cardiac troponin-T immunoassays | |
| Lee et al. | The anion gap is a predictive clinical marker for death in patients with acute pesticide intoxication | |
| Pierzynowska et al. | Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation | |
| Fazio et al. | Lithium concentration in biological samples and gender difference in athletic horses | |
| Lehmann et al. | Symmetrical dimethylarginine as a diagnostic parameter in Hermann's tortoises (Testudo hermanni) | |
| CA2890518A1 (en) | Methods for determining if an animal's metabolism is ketogenic | |
| Hostovská et al. | Effect of different types of exercise on salivary biochemical indices in the horse | |
| Sasanelli et al. | Acute-phase proteins in dogs naturally infected with Leishmania infantum during and after long-term therapy with allopurinol | |
| Camacho et al. | Validation of a reference interval for symmetric dimethylarginine in healthy goats and its comparison to values in goats with obstructive urolithiasis | |
| Shishikura et al. | The dynamics of cell-free DNA from urine and blood after a full marathon | |
| Bouda et al. | Blood acid–base and plasma electrolyte values in healthy ostriches: The effect of age and sex | |
| Guess et al. | Longitudinal Evaluation of Serum Symmetric Dimethylarginine (SDMA) and Serum Creatinine in Dogs Developing Chronic Kidney Disease. | |
| Rzymski et al. | Blood glucose level as an insufficient indicator of feline diabetes mellitus: a case report. | |
| WO2019049705A1 (ja) | アルツハイマー症診断装置及び方法 | |
| Golightly et al. | 3 Chapter 3: Serum levels of brain-derived neurotrophic factor as a potential welfare biomarker | |
| Pošivák et al. | Comparison of some biochemical and mineral indices among Norik breed Muráň Plain type and Hucul breed mares | |
| Golightly et al. | Serum concentrations of brain-derived neurotrophic factor as a potential biomarker of swine welfare | |
| Furtado et al. | Sarcopenia e inflamación en pacientes sometidos a hemodiálisis | |
| Tüfekçi et al. | Determination of serum cortisol levels as a stress marker in hospitalized dogs | |
| Barros-Aragão et al. | Comparison of cerebrospinal fluid biomarkers in patients with severe COVID-19 neurological outcomes and Alzheimer’s disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20181114 |